INTI

Inhibitor Therapeutics, Inc. [INTI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INTI Stock Summary

Top 10 Correlated ETFs

INTI

Top 10 Correlated Stocks

INTI

In the News

INTI Financial details

Company Rating
-
Market Cap
13.33M
Income
-2.94M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
0.75
Forward P/E
-
PEG
-0.05
P/S
-
P/B
2.73
P/C
-
P/FCF
1.78
Quick Ratio
60.97
Current Ratio
61.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
-154.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
74.36%
-
-
-
-
SMA20
-28.57%
SMA50
-16.67%
SMA100
-37.5%
Inst Own
-
Inst Trans
-
ROA
244%
ROE
316%
ROC
-0.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.013-0.3
52W High
-
52W Low
-
RSI
35.85
Rel Volume
0.28
Avg Volume
9K
Volume
2.5K
Perf Week
-14.72%
Perf Month
-34.4%
Perf Quarter
-44.22%
Perf Half Y
-47.03%
-
-
-
-
Beta
-0.768
-
-
Volatility
0%, 0.01%
Prev Close
6.6%
Price
0.04264
Change
3.5%

Something similar

Top by Market Cap
FXAIX
AMZN
VOO
FB2A.DE
VFINX
Top Correlated ETFs
DSB.PA
HYDR
HDGB.L
DRSK
HMMJ.TO
Top Correlated Stocks
RMNI
PLUN.DE
2197.HK
FLK.L
AURA
Similar Market Cap
MLPHO.PA
FEUZ
ALDA
AYTU
ENG

Company Profile

Healthcare Biotechnology
  • Volume Average 9K
  • Market Capitalization 13.33M
  • Employee 3
  • CEO Dr. Francis E. O'Donnell Jr., M.D.
  • Headquarters Tampa,FL,US
  • IPO Date 2013-09-13
  • Website https://www.inhibitortx.com

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.